THE WOODLANDS, Texas, May 06, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the Company will release its first quarter 2025 financial results on Tuesday, May 13 ...

Oral presentation highlights additional data from PROGRESS Phase 2b study of pilavapadin supporting selection of 10mg as optimal dose for Phase ...

Lexicon Pharmaceuticals won't take no for an answer. The Texas pharma—convinced of the value of its diabetes candidate sotagliflozin—has clapped back at its latest rejection from the FDA, asking to be ...

“It's a wonderful morning for Lexicon, our scientists, clinicians and the patients and principal investigators,” summed up CEO and Director Lonnel Coats, as the biotech reported results from a phase 2 ...

Sanofi is set to pay Lexicon Pharmaceuticals $260 million (€236 million) to get out of a diabetes pact. The dissolution of the alliance follows the generation of mixed clinical data on Zynquista in ...

THE WOODLANDS, Texas, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced it has received a complete response letter (CRL) from the U.S. Food and Drug ...

Sanofi has terminated a nearly four-year-old, potentially $1.7 billion-plus collaboration with Lexicon Pharmaceuticals to develop ZynquistaTM (sotagliflozin) for type 1 and type 2 diabetes after the ...

New Research from Lexicon Branding Finds Most Consumers Don't Notice -- or Care About -- a Company's URL Extension Recent consumer study challenges the conventional wisdom that a .com domain is ...

Lexicon Pharmaceuticals spent years jumping and often falling over regulatory hurdles for its new heart drug Inpefa, but, after finally getting an FDA approval this year, it’s now turning to Tom ...

An explosion in data volumes, proliferation of platforms, and evolving regulatory requirements has made effective monitoring of employee communications much more difficult. The remote and hybrid ...